This is a preclinical development update with no financial metrics released. Traders should monitor for upcoming IND submission in Q4 2026 and any future clinical trial initiations, which could serve as catalysts. The lack of revenue or earnings data limits near-term trading impact.
Price Chart
Executive Summary
Curanex Pharmaceuticals issued a press release highlighting operational progress in advancing its lead asset, Phyto-N, toward a planned IND submission for ulcerative colitis in Q4 2026. The update covers advancements in manufacturing, toxicology studies, intellectual property, and regulatory planning, but includes no actual financial results or revenue/earnings data.
Key Facts
- Company provided a business update alongside its 2025 Form 10-K filing.
- Advanced CMC activities, including completion of a pilot-scale GMP batch of Phyto-N in February 2026.
- Completed dose-range finding toxicology study with no significant adverse findings.
- Targeting IND submission for ulcerative colitis in Q4 2026 and Phase 1 trials in Australia pending clearance.
- Filed a PCT patent application in March 2025 covering multiple disease areas.
- Pipeline includes ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout.
- Company believes it has sufficient funding to support operations for at least 12 months post-IPO.
Financial Impact
No financial performance data (revenue, EPS) disclosed; no immediate dilution or monetization event.
Risk Factors
- Forward-looking statements carry high uncertainty; IND submission and clinical trials are subject to regulatory delays or failures.
- No revenue-generating products; company remains in pre-revenue development stage.
- Market cap of $14M is speculative given absence of clinical data or commercial products.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265068 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $4.77 | awaiting T+20 | — | $4.82 (+1.15%) |
Aug 17, 2026 10w ago | 8-K | $4.44 $4.37 | ▼ −1.69% | ▼ −0.70% | $4.82 (+8.56%) |
May 14, 2026 23w ago | 8-K | $0.3130 $0.3210 | ▲ +2.56% | ▲ +3.41% | $4.82 (+1439.94%) |
May 14, 2026 23w ago | Press Release | $0.3130 $0.3210 | ▲ +2.56% | ▲ +3.41% | $4.82 (+1439.94%) |
May 7, 2026 24w ago | 8-K | $0.3160 $0.3260 | ▲ +3.16% | ▲ +0.03% | $4.82 (+1425.32%) |
Apr 2, 2026 29w ago | 8-K | $0.4900 $0.4170 | ▼ −14.90% | ▼ −24.77% | $4.82 (+883.67%) |
Mar 30, 2026 30w ago | Press Release | $0.5110 $0.4300 | ▼ −15.85% | ▼ −25.27% | $4.82 (+843.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers